K A Ault

Summary

Affiliation: University of Iowa
Country: USA

Publications

  1. pmc Antibodies to the chlamydial 60 kilodalton heat shock protein in women with tubal factor infertility
    K A Ault
    Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, USA
    Infect Dis Obstet Gynecol 6:163-7. 1998
  2. ncbi request reprint A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Vaccine 22:3004-7. 2004
  3. ncbi request reprint Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Obstet Gynecol Clin North Am 30:809-17. 2003
  4. ncbi request reprint Gonorrhea and chlamydia infection among women visiting family planning clinics: racial variation in prevalence and predictors
    Lisa A Einwalter
    University of Iowa, College of Public Health, Iowa City, IA, USA
    Perspect Sex Reprod Health 37:135-40. 2005
  5. pmc Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists
    Janice C Raley
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Infect Dis Obstet Gynecol 12:127-33. 2004
  6. pmc Does rubella immunity predict measles immunity? A serosurvey of pregnant women
    Colleen M Kennedy
    Department of Obstetrics and Gynecology, Roy J and Lucille A Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Infect Dis Obstet Gynecol 2006:13890. 2006
  7. pmc Telomerase activity as a potential diagnostic marker for triage of abnormal Pap smears
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa, USA
    J Low Genit Tract Dis 9:93-9. 2005
  8. ncbi request reprint Chlamydia trachomatis enhances the expression of matrix metalloproteinases in an in vitro model of the human fallopian tube infection
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa College of Medicine, Iowa City, USA
    Am J Obstet Gynecol 187:1377-83. 2002
  9. ncbi request reprint Surfactant proteins A and D enhance the phagocytosis of Chlamydia into THP-1 cells
    Rebecca E Oberley
    Department of Anatomy and Cell Biology, University of Iowa College of Medicine, Iowa City, IA 52242, USA
    Am J Physiol Lung Cell Mol Physiol 287:L296-306. 2004
  10. ncbi request reprint Surfactant protein D is present in the human female reproductive tract and inhibits Chlamydia trachomatis infection
    Rebecca E Oberley
    Department of Anatomy and Cell Biology, University of Iowa, Carver College of Medicine, Iowa City, IA 52242, USA
    Mol Hum Reprod 10:861-70. 2004

Collaborators

Detail Information

Publications24

  1. pmc Antibodies to the chlamydial 60 kilodalton heat shock protein in women with tubal factor infertility
    K A Ault
    Department of Obstetrics and Gynecology, University of Kansas Medical Center, Kansas City, USA
    Infect Dis Obstet Gynecol 6:163-7. 1998
    ..Our objective was to study the relationship between antibody response to 60 kilodalton chlamydial hsp and tubal factor infertility (TFI)...
  2. ncbi request reprint A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Vaccine 22:3004-7. 2004
    ..Peak anti-HPV18 geometric mean titers (GMT) in vaccines were 60-fold greater than those observed in women following natural HPV18 infection. Further studies of a multivalent HPV L1 VLP vaccines are warranted...
  3. ncbi request reprint Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA
    Obstet Gynecol Clin North Am 30:809-17. 2003
    ..Gynecologists should be familiar with these therapies and their potential short-comings. A recently reported clinical trial has raised hopes that HPV and its sequelae may be prevented by vaccination...
  4. ncbi request reprint Gonorrhea and chlamydia infection among women visiting family planning clinics: racial variation in prevalence and predictors
    Lisa A Einwalter
    University of Iowa, College of Public Health, Iowa City, IA, USA
    Perspect Sex Reprod Health 37:135-40. 2005
    ..Because of the potential impact of these infections on women's reproductive health, it is important to determine whether different factors are predictive of infection in women of different races...
  5. pmc Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists
    Janice C Raley
    Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Infect Dis Obstet Gynecol 12:127-33. 2004
    ..Vaccination for HPV may become a routine part of office gynecology. We surveyed members of the American College of Obstetricians and Gynecologists (ACOG) to determine their attitudes to HPV vaccination...
  6. pmc Does rubella immunity predict measles immunity? A serosurvey of pregnant women
    Colleen M Kennedy
    Department of Obstetrics and Gynecology, Roy J and Lucille A Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA
    Infect Dis Obstet Gynecol 2006:13890. 2006
    ..This study was undertaken to determine whether rubella immunity infers measles immunity in pregnant women...
  7. pmc Telomerase activity as a potential diagnostic marker for triage of abnormal Pap smears
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa, Iowa City, Iowa, USA
    J Low Genit Tract Dis 9:93-9. 2005
    ..To determine whether there is an association between high levels of telomerase and premalignant cervical disease and to provide a preliminary analysis of telomerase activity as a potential triage strategy...
  8. ncbi request reprint Chlamydia trachomatis enhances the expression of matrix metalloproteinases in an in vitro model of the human fallopian tube infection
    Kevin A Ault
    Department of Obstetrics and Gynecology, University of Iowa College of Medicine, Iowa City, USA
    Am J Obstet Gynecol 187:1377-83. 2002
    ..Our objective was to describe the production of two matrix metalloproteinases in response to chlamydial infection in vitro...
  9. ncbi request reprint Surfactant proteins A and D enhance the phagocytosis of Chlamydia into THP-1 cells
    Rebecca E Oberley
    Department of Anatomy and Cell Biology, University of Iowa College of Medicine, Iowa City, IA 52242, USA
    Am J Physiol Lung Cell Mol Physiol 287:L296-306. 2004
    ..In addition, the chlamydial pathogens internalized in the presence of collectins are able to grow and replicate in the THP-1 cells after phagocytosis...
  10. ncbi request reprint Surfactant protein D is present in the human female reproductive tract and inhibits Chlamydia trachomatis infection
    Rebecca E Oberley
    Department of Anatomy and Cell Biology, University of Iowa, Carver College of Medicine, Iowa City, IA 52242, USA
    Mol Hum Reprod 10:861-70. 2004
    ..In conclusion, we detected SP-D in the female reproductive tract and determined that one of the functions of the SP-D protein may be to protect cervical epithelial cells from infection by C. trachomatis...
  11. ncbi request reprint A role for surfactant protein D in innate immunity of the human prostate
    Rebecca E Oberley
    Department of Anatomy and Cell Biology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Prostate 65:241-51. 2005
    ..In the present study, we found that SP-D is produced in the human prostate where it may play a role in innate immunity...
  12. pmc Epidemiology and natural history of human papillomavirus infections in the female genital tract
    Kevin A Ault
    Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA 30303, USA
    Infect Dis Obstet Gynecol 2006:40470. 2006
    ..New prophylactic HPV vaccines promise to dramatically reduce the incidence of HPV infection, genital warts, and cytologic abnormalities...
  13. ncbi request reprint Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, R Prof Antonio Prudente 109, 4th Floor, 01509 010 Sao Paulo, SP, Brazil
    Vaccine 24:5571-83. 2006
    ..Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported...
  14. ncbi request reprint Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial
    Constance Mao
    Department of Obstetrics and Gynecology and Epidemiology, University of Washington, Seattle, Washington 98104 2499, USA
    Obstet Gynecol 107:18-27. 2006
    ..Whether protection lasts longer than 18 months and, thus, impacts rates of cervical intraepithelial neoplasia (CIN) 2-3 has not yet been established. We present results from an HPV16 L1 VLP vaccine trial through 48 months...
  15. ncbi request reprint Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review
    Kevin A Ault
    Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
    Obstet Gynecol Surv 61:S26-31. 2006
    ....
  16. ncbi request reprint Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
    Luisa L Villa
    Department of Virology, Ludwig Institute for Cancer Research, Sao Paulo, Brazil
    Lancet Oncol 6:271-8. 2005
    ....
  17. ncbi request reprint A controlled trial of a human papillomavirus type 16 vaccine
    Laura A Koutsky
    Department of Epidemiology, University of Washington, Seattle, USA
    N Engl J Med 347:1645-51. 2002
    ..Although most infections are benign, some progress to anogenital cancer. A vaccine that reduces the incidence of HPV-16 infection may provide important public health benefits...
  18. ncbi request reprint Human papillomavirus vaccines and the potential for cross-protection between related HPV types
    Kevin A Ault
    Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Jr Drive, S E Atlanta, Georgia 30303, USA
    Gynecol Oncol 107:S31-3. 2007
    ..Over a period of 6 months, cross-protection was observed against persistent infections with HPV-45, -31 and -52, and at 12 months, modest protection was demonstrated against persistent infections with 12 combined oncogenic HPV types...
  19. ncbi request reprint Regulation of surfactant protein D in the mouse female reproductive tract in vivo
    Rebecca E Oberley
    Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206, USA
    Mol Hum Reprod 13:863-8. 2007
    ..These data are suggestive that SP-D may play a role in innate immunity in the female reproductive tract in vivo...
  20. ncbi request reprint Long-term efficacy of human papillomavirus vaccination
    Kevin A Ault
    Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Drive, Atlanta, GA 30064, USA
    Gynecol Oncol 107:S27-30. 2007
    ..Population-based long-term efficacy trials conducted in these countries aim to investigate the long-term efficacy of HPV vaccination with regard to invasive cervical cancer, and the results of these trials are awaited with interest...
  21. ncbi request reprint Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
    Kevin A Ault
    Department of Gynecology and Obstetrics, Emory University School of Medicine, 69 Jesse Hill Jr Drive, SE, Atlanta, GA 30303, USA
    Lancet 369:1861-8. 2007
    ..In this combined analysis of four clinical trials we assessed the effect of prophylactic HPV vaccination on these diseases...
  22. ncbi request reprint Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine
    Christophe Fraser
    Imperial College London, London, UK
    Vaccine 25:4324-33. 2007
    ....
  23. pmc Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection
    Kyle H Ramsey
    Department of Microbiology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL 60515, USA
    Infect Dis Obstet Gynecol 11:81-7. 2003
    ..We postulated that either oral or vaginal administration of the immune response modifier imiquimod would decrease vaginal shedding of Chlamydia trachomatis, mouse pneumonitis strain (MoPn), in a murine model...
  24. doi request reprint Human papillomavirus vaccines: an update for gynecologists
    Kevin A Ault
    Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Obstet Gynecol 51:527-32. 2008
    ..This review will discuss the natural history and epidemiology of HPV, the diseases associated with these infections and current clinical usage of this vaccine. Future developments in this area will also be discussed...